{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:18:12Z","timestamp":1791260292522,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.trsl.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T18:42:50Z","timestamp":1654800170000},"page":"49-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders"],"prefix":"10.1016","volume":"249","author":[{"given":"JOHN","family":"Malona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CLAUDIO","family":"CHUAQUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BORIS M.","family":"SELETSKY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISA","family":"BEEBE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUSAN","family":"CANTIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL VAN","family":"KALKEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KELLY","family":"FAHNOE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHIGANG","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BETH","family":"BROWNING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HILARY","family":"SZABO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LOUISE A.","family":"KOOPMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAMAS","family":"ORAVECZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOSEPH J.","family":"MCDONALD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCISCO","family":"RAMIREZ-VALLE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAJULA","family":"GAUR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOFI A.","family":"MENSAH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL","family":"THOMAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAMIE N.","family":"CONNARN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HAIQING","family":"HU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATTHEW D.","family":"ALEXANDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALAN F.","family":"CORIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2022.06.005_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-alpha\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.trsl.2022.06.005_bib0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/CEG.S110546","article-title":"Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab","volume":"10","author":"Jauregui-Amezaga","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2022.06.005_bib0003","doi-asserted-by":"crossref","first-page":"I65","DOI":"10.1136\/ard.58.2008.i65","article-title":"Etanercept: therapeutic use in patients with rheumatoid arthritis","volume":"58","author":"Garrison","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2022.06.005_bib0004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14712598.2018.1468884","article-title":"Biologics for treating axial spondyloarthritis","volume":"18","author":"Jones","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.trsl.2022.06.005_bib0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2022.06.005_bib0007","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2174\/156802608786264245","article-title":"Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008","volume":"8","author":"Pettus","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2022.06.005_bib0009","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3899\/jrheum.100602","article-title":"A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis","volume":"38","author":"Genovese","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0010","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cgh.2005.11.013","article-title":"Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Schreiber","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0011","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1515\/hsz-2013-0197","article-title":"What goes up must come down: molecular basis of MAPKAP kinase 2\/3-dependent regulation of the inflammatory response and its inhibition","volume":"394","author":"Gaestel","year":"2013","journal-title":"Biol Chem"},{"issue":"Suppl 1","key":"10.1016\/j.trsl.2022.06.005_bib0012","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","article-title":"\u201cGo upstream, young man\u201d: lessons learned from the p38 saga","volume":"69","author":"Hammaker","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2022.06.005_bib0013","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.110.166173","article-title":"A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation","volume":"333","author":"Mourey","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2022.06.005_bib0014","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1093\/emboj\/18.18.4969","article-title":"The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism","volume":"18","author":"Winzen","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.trsl.2022.06.005_bib0015","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1128\/MCB.26.6.2399-2407.2006","article-title":"Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine\/uridine-rich element","volume":"26","author":"Hitti","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002977","article-title":"The p38\/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation","volume":"8","author":"Tiedje","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.trsl.2022.06.005_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/10061","article-title":"MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis","volume":"1","author":"Kotlyarov","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0018","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.177.3.1913","article-title":"MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis","volume":"177","author":"Hegen","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0019","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1021\/bi0495073","article-title":"Discovery and characterization of a substrate selective p38alpha inhibitor","volume":"43","author":"Davidson","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.trsl.2022.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1084\/jem.20172063","article-title":"Selective inhibition of the p38alpha MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals","volume":"215","author":"Wang","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2022.06.005_bib0021","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1021\/acs.jmedchem.5b01457","article-title":"Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2): medicinal chemistry efforts to lead small molecule inhibitors to clinical trials","volume":"59","author":"Fiore","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0022","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00928361","article-title":"Physiological concentrations of purines and pyrimidines","volume":"140","author":"Traut","year":"1994","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0024","doi-asserted-by":"crossref","first-page":"30046","DOI":"10.1074\/jbc.M001010200","article-title":"A novel method for measurement of submembrane ATP concentration","volume":"275","author":"Gribble","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jmb.2007.03.004","article-title":"Structural basis for a high affinity inhibitor bound to protein kinase MK2","volume":"369","author":"Hillig","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2022.06.005_bib0027","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0028","series-title":"MK2 inhibitors and uses thereof. US 2016\/0075720 A1","author":"Alexander","year":"2016"},{"key":"10.1016\/j.trsl.2022.06.005_bib0029","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1016\/j.bmcl.2009.02.017","article-title":"Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency","volume":"19","author":"Anderson","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.trsl.2022.06.005_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trsl.2022.06.005_bib0031","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trsl.2022.06.005_bib0032","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trsl.2022.06.005_bib0033","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trsl.2022.06.005_bib0034","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trsl.2022.06.005_bib0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/pro.3330","article-title":"MolProbity: more and better reference data for improved all-atom structure validation","volume":"27","author":"Williams","year":"2018","journal-title":"Protein Sci"},{"key":"10.1016\/j.trsl.2022.06.005_bib0036","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ab.2006.03.003","article-title":"Optimal Sox-based fluorescent chemosensor design for serine\/threonine protein kinases","volume":"352","author":"Shults","year":"2006","journal-title":"Anal Biochem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0037","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0038","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.biochem.1c00422","article-title":"SMaSh: A streptavidin mass shift assay for rapidly quantifying target occupancy by irreversible inhibitors","volume":"60","author":"Labenski","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.trsl.2022.06.005_bib0039","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/dvdy.21623","article-title":"Gene nomenclature guidelines for the planarian Schmidtea mediterranea","volume":"237","author":"Reddien","year":"2008","journal-title":"Dev Dyn"},{"key":"10.1016\/j.trsl.2022.06.005_bib0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/019262339702500411","article-title":"HLA-B27 transgenic rats: animal model of human HLA-B27-associated disorders","volume":"25","author":"O'Neill","year":"1997","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0041","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.4049\/jimmunol.175.4.2438","article-title":"HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response","volume":"175","author":"Turner","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0042","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3389\/fimmu.2017.00920","article-title":"Innate immune activation can trigger experimental spondyloarthritis in HLA-B27\/Hubeta2m transgenic rats","volume":"8","author":"van Tok","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0043","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0044","doi-asserted-by":"crossref","first-page":"32768","DOI":"10.1038\/srep32768","article-title":"Efficacy and safety of TNF-alpha inhibitors for active ankylosing spondylitis patients: multiple treatment comparisons in a network meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2022.06.005_bib0045","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2022.06.005_bib0046","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2022.06.005_bib0047","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4155\/fmc.09.98","article-title":"Low-molecular-weight MK2 inhibitors: a tough nut to crack!","volume":"1","author":"Schlapbach","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0048","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/jm201322r","article-title":"A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors","volume":"55","author":"Chen","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0049","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrd1500","article-title":"Biochemical mechanisms of drug action: what does it take for success?","volume":"3","author":"Swinney","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2022.06.005_bib0050","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2022.06.005_bib0051","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/cyto.1997.0289","article-title":"Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications","volume":"10","author":"Petrovsky","year":"1998","journal-title":"Cytokine"},{"key":"10.1016\/j.trsl.2022.06.005_bib0052","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/jpet.109.158329","article-title":"Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation","volume":"331","author":"Hope","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trsl.2022.06.005_bib0053","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1167\/iovs.09-3674","article-title":"Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function","volume":"51","author":"Du","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.trsl.2022.06.005_bib0054","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.4049\/jimmunol.176.3.1899","article-title":"Essential role of MAPK phosphatase-1 in the negative control of innate immune responses","volume":"176","author":"Salojin","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2022.06.005_bib0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1471-4159.2007.04535.x","article-title":"Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia","volume":"102","author":"Zhou","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0056","doi-asserted-by":"crossref","first-page":"e75527","DOI":"10.1371\/journal.pone.0075527","article-title":"Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK","volume":"8","author":"Nomura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2022.06.005_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138542","article-title":"MAP-kinase activated protein kinase 2 links endothelial activation and monocyte\/macrophage recruitment in arteriogenesis","volume":"10","author":"Limbourg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2022.06.005_bib0058","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-2094-9-34","article-title":"5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2\/MCP-1 expression in IFN-gamma-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability","volume":"9","author":"Lee","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.trsl.2022.06.005_bib0059","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm501038s","article-title":"Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors","volume":"58","author":"Cumming","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2022.06.005_bib0060","article-title":"Methotrexate for ankylosing spondylitis","volume":"28","author":"Chen","year":"2013","journal-title":"Cochrane Database of Syst Rev."},{"key":"10.1016\/j.trsl.2022.06.005_bib0061","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422001384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524422001384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:46:44Z","timestamp":1761828404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524422001384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":61,"alternative-id":["S1931524422001384"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2022.06.005","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of CC-99677, a selective targeted covalent MAPKAPK2 (MK2) inhibitor for autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}